AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth

15th November 2017 Uncategorised 0

Ovarian cancer treatment has changed dramatically, and with several new drugs now duking it out in that market, the battle for share is changing, too. If recent numbers—and a new doctor survey—are any indication, Tesaro’s Zejula is in the lead. But that could change.

More: AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Source: fierce